LSE - Delayed Quote GBp

Venture Life Group plc (VLG.L)

53.00
+3.00
+(6.00%)
At close: 4:27:02 PM GMT+1
Loading Chart for VLG.L
  • Previous Close 50.00
  • Open 50.40
  • Bid 51.00 x --
  • Ask 53.00 x --
  • Day's Range 50.00 - 53.22
  • 52 Week Range 32.00 - 58.00
  • Volume 461,041
  • Avg. Volume 474,667
  • Market Cap (intraday) 67.87M
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 53.00
  • EPS (TTM) 0.01
  • Earnings Date Jun 19, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 24, 2018
  • 1y Target Est 100.00

Venture Life Group plc develops and commercializes healthcare products in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms related to rosacea; Bioscalin for the cosmetic treatment and prevention of hair loss, hair thinning, and baldness; and skincare solutions under the brand Lubatti. In addition, the company offers women's healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ brand. Further, it provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos, as well as Glucogel for the treatment of hypoglycaemia. Additionally, the company offers ENT care products comprising Earol, for the removal of ear wax; EarolSwim, an invisible ear plugs for protecting the ears from water ingress; Baby Earol, an ear spray for babies; and Sterinase for relieving blocked noses, clearing nasal passages, and preventing the risk of allergic reactions and infections. It also provides oncology support products, such as Pomi-T, used for the management of prostate-specific antigen levels in prostate cancer; Gelclair, a muco-adhesive oral rinse for the treatment of Oral Mucositis; and Xonrid, a hyaluronic acid based topical gel, for the prevention and treatment of Radiation Induced Dermatitis. The company was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.

www.venture-life.com

165

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VLG.L

View More

Performance Overview: VLG.L

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

VLG.L
35.03%
FTSE 100 (^FTSE)
6.26%

1-Year Return

VLG.L
30.86%
FTSE 100 (^FTSE)
2.91%

3-Year Return

VLG.L
51.43%
FTSE 100 (^FTSE)
16.34%

5-Year Return

VLG.L
18.97%
FTSE 100 (^FTSE)
49.74%

Compare To: VLG.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VLG.L

View More

Valuation Measures

As of 5/15/2025
  • Market Cap

    64.03M

  • Enterprise Value

    79.60M

  • Trailing P/E

    92.59

  • Forward P/E

    7.94

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.32

  • Price/Book (mrq)

    0.86

  • Enterprise Value/Revenue

    1.55

  • Enterprise Value/EBITDA

    8.24

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.44%

  • Return on Assets (ttm)

    1.56%

  • Return on Equity (ttm)

    1.00%

  • Revenue (ttm)

    51.41M

  • Net Income Avi to Common (ttm)

    742k

  • Diluted EPS (ttm)

    0.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.58M

  • Total Debt/Equity (mrq)

    28.45%

  • Levered Free Cash Flow (ttm)

    6.39M

Research Analysis: VLG.L

View More

People Also Watch